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The optimism surrounding multi-
stakeholder research initiatives
does not match the clear view of
policies that are needed to exploit
the potential of these collabora-
tions. Here we propose some
action items that stem from the
integration between research
advancements with the perspec-
tives of patient-advocacy orga-
nizations, academia, and industry.
There is hope about the growing collabo-
ration in biomedical research between
academia, industry, and patient-advocacy
organizations. Declarations of intents and
partnerships have been launched and
capital has been invested in large multista-
keholder efforts (e.g., the European Union’s
Innovative Medicines Initiative) and in
smaller programmes (e.g., the Collabora-
tive Network Awards of the Progressive
Multiple Sclerosis Alliance) that, despite
their size, have been capable of attracting
the interest of hundreds of researchers in
dozens of international networks.
Despite the reasons to be optimistic,
including the flow of resources and the
different models that exist for collabora-
tion, some concern is emerging about the
ability of these partnerships to evolve in a
coordinated and productive manner and
whether these partnerships can match
patients’ needs [1,2]. In the face of these
concerns, suggestions have been put for-
ward, ranging from models of collabora-
tion in specific diseases [3] to measures to
improve the impact of philanthropy [4].
While all these suggestions provide pre-
cious inputs, they still do not ensure that
Multistakeholder Research Initiatives
(MSRIs) will deliver their full potential
and advance over time with the commit-
ment of all relevant stakeholders. As put
forward in the setting of social-ecological
systems [5], and by recent calls for pro-
posals (e.g., the H2020 SWAFS-05-2017
call for proposals: New Constellations of
Changing Institutions and Actors), collab-
orative initiatives still present challenges
that call for innovative solutions.
As patients’ representatives, researchers,
and experts in business ethics, we have
been involved in collaborative efforts
(often together), and have been con-
fronted with the difficulties of sustaining
and advancing research through tradi-
tional models. Based on our experience,
we here suggest some new action items
that integrate scientific progress and
stakeholders’ perspectives, toward
achieving a collective impact of MSRIs.
We also propose that the step that needs
to be taken to implement these or other
items is to invest in the development of a
‘science of collective sustainability’ that
identifies and accompanies those actions
that are most relevant for all the stake-
holders, individually and as a group.
The main neurodegenerative diseases
can exemplify the difficulties that clinical
research faces in some conditions more
than in others. Their pathophysiology is a
complex interplay between neurodegen-
erative and inflammatory processes, with
different cell types involved; the diseased
tissue is very difficult to access; clinical
course is often slow; and appropriate
experimental models are frequently miss-
ing. These factors are responsible not
only for the difficulty in identifying ‘drug-
gable’ targets, but also for the lack of
satisfactory outcome measures and reli-
able biomarkers that may accelerate the
clinical evaluation of basic science
acquisitions. Furthermore, it is difficult to
fully understand why any given therapeu-
tic attempt has failed (positive biological
effects, on a given type of insult, may be
overruled by other mechanisms of dam-
age not targeted by the single treatment).
To overcome the above issues, a series of
in vitro and in vivo models have been
created in the attempt to recapitulate
aspects of human central nervous system
(CNS) pathophysiology. Sophisticated
neuroimaging and neurophysiology tech-
niques have been developed. However,
none of these attempts has proven to be a
‘game changer’ and there is no trial
design that promises to improve both trial
duration and consistency of the results.
Now that molecular mechanisms, shared
in common across multiple diseases, are
being increasingly described [6,7], new
opportunities may come from a new inte-
gration between the above approaches
and research on other, often ‘under-
served’, diseases. Among the ‘under-
served’ diseases, we find conditions
that ‘simplify’ the above-mentioned prob-
lems, either because the pathophysiology
is less complex and better understood (e.
g., diseases that primarily affect a single
cell type, such as Nasu-Hakola disease
for microglia or Alexander’s disease for
astrocytes, or the neuropathological sim-
ilarities between Niemann-Pick disease
and Alzheimer’s disease), or because
the affected tissue is more accessible
(as in peripheral nervous system condi-
tions), or because the disease course is
faster (e.g., in neurological paraneoplastic
diseases). Clinical trials in these diseases
may unveil a biological efficacy that may
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be more difficult to demonstrate in more
common CNS diseases, where different
types of damage converge. Interestingly,
this is even truer for symptomatic thera-
pies (often overlooked but of paramount
importance for patients), where shared
mechanisms can be successfully tar-
geted in different diseases [8].
Unmasking the positive effects of a treat-
ment on single disease processes would
also enable the rational construction of
combination therapies, possibly the only
approach that, in the short/medium term,
may be able to combat the different types
of damage that characterize the more
common diseases.
On these bases, encouraging coordi-
nated clinical research initiatives referring
to diseases that share pathophysiology at
different levels of complexity might be a
new objective for patient organizations.
Collaboration may bring several advan-
tages: ‘companion clinical trials’ may be
imagined where trials in common dis-
eases are flanked by trials in ‘simpler’,
underserved diseases, selected accord-
ing to shared pathophysiological princi-
ples. Developing therapies across
different diseases may also help develop
the economies of scales that may pro-
mote the industrialization of rare disease
therapy development [9]. Moreover, clini-
cal false negative results may be better
understood, while positive results may
de-risk industrial investments and be per-
ceived as more reliable by regulatory
authorities. At the same time, this would
offer a chance to patients with diseases
that rarely happen to be the object of
properly designed and conducted clinical
trials. Finally, any initiative that raises
awareness about rare/underserved dis-
eases, among those who routinely deal
with more frequent disorders, might
reduce the probability of diagnostic errors
that all too often occur in qualified clinical
settings.
To capture these opportunities (summa-
rized in Figure 1), the adaptation of patient
advocacy to biomedical research will
require a step in its evolution. The growing
understanding of how common principles
in pathophysiology are shared should
convince patient-advocacy organizations
to look beyond one’s own illness and share
resources according to shared biology (the
development of a common classification
system to uniformly identify priorities
across diverse funder types and research
portfolios will be key to finalize the pro-
cess). This would also coordinate well with
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Figure 1. Sequence of Concrete Actions and Returns That Are Relevant for all the Stakeholders,
Individually and as a Group.
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companies evaluating the same drug in
different diseases (e.g., laquinimod in mul-
tiple sclerosis and in Huntington’s disease;
repurposing, Box 1).
Like other goals in MSRI, the policies
presented in this article are collective
action problems that need sustainable
and innovative solutions. It will be difficult
to achieve the suggested objectives/
advancements without investing in the
development of new models of collabo-
rative and sustainable research gover-
nance (‘a science of collective
sustainability’). These are difficult tasks
(as the reduction in preclinical deals
between industry and academia seems
to reflect [10]) but could be facilitated if
all the stakeholders maintain the same
perception of patients’ priorities.
A strong focus on patient-oriented
research is already at the root of different
ongoing MSRIs. The remaining challenge
is that stakeholders have to contribute
jointly negotiated solutions to common
action problems (mission), while advocat-
ing their own return of investment. No
single blueprint exists for how to meet
this challenge. ‘Shared measurements
of impact’ are among the tools that
may, in practice, facilitate this process
[11]. However, conventional metrics in
biomedical research are not normally
designed to represent different claims of
different stakeholders [12]. Insights are
emerging from recent research that have
stimulated discussion on the need for
more participatory forms of research gov-
ernance and the need to revisit some of
the foundational elements of the Collec-
tive Impact Model (‘movement building’
or, as spelled out by Al Etmanski and
Vickie Cammack, two celebrated social
innovators, ‘act like an organization but
think like a movement’ [13]). Building on
this vision, a Collective Impact Research
Framework could be adopted by each
research initiative, according to its mis-
sion: ‘when a measure becomes a target
it ceases to be a good measure’ [14]. This
may head toward better and participatory
decision making of the relevant stake-
holders in the design of the agenda (Com-
munity Aspiration), funding programmes
and evaluation procedures (Strategic
Learning), and policies (High Leverage
Activities and Inclusive Community
Engagement). Within this framework, an
Integrated Accountability Model (IAM) [15]
applied to MSRIs in four different dimen-
sions (efficacy, excellence, efficiency, and
social) is a prospective model to be imple-
mented at the start of a research initiative,
engaging stakeholders in defining metrics
in a bottom-up approach, rather than a
single performance assessment system.
The IAM model conveys a balanced ‘sus-
tainable’ way to deliver an integrated
report, thanks to processes of stake-
holder empowerment along the whole
framework.
Within this frame, in measuring the impact
of the research in health research organiza-
tions, it is fundamental to consider patients
as key stakeholders throughout the entire
measurement process. The development
of practices, methodologies, and mea-
sures for patient engagement deserves
attention, resources, and structures in
which these strategies are made operative
and new professionals are trained.
In a time of considerable progress, basic
science advancements offer opportuni-
ties for the development of new therapies.
However, to really move the field forward,
basic science progress should also stim-
ulate innovative policies and actions that
may reshape and streamline collaboration
in clinical research. These will need to be
applied and prospectively adapted to
changes, to ensure that the best possible
collective impact is maintained over time,
for all the stakeholders involved.
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Box 1. Collective Actions to Unlock the Potential of Repurposing
So far, repurposing (i.e., finding new therapeutic indications for existing compounds) has not delivered its full
potential. In the hands of academia and patient-advocacy organizations it generates new knowledge but not
the financial return to sustain the transition from phase 2 to registration trials. Conversely, industry has a high
success rate in registering chemically modified, repurposed compounds but, often, it does not improve the
‘old’ drug to a point that justifies the increase in healthcare costs.
There are good reasons (in our opinion still not fully realized by current MSRI) for companies, academia, and
patients to act jointly in the field.
It is in the companies’ interest to sustain patient-advocacy organizations and academia in implementing
early-phase repurposing trials with innovative designs and biomarkers (because of the huge investments,
these kind of ‘experiments’ are hardly feasible in a traditional drug development process).
It is in the interest of patients and academia to advocate for policy changes that incentivize companies to
generate intellectual property by testing new dose levels, drug combinations, and routes of administration.
These approaches are more likely to advance treatments compared with strategies that, presently, are less
‘challenging’ and, therefore, more frequently adopted (e.g., chemical modifications of the ‘old’ compound).
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The molecular mechanisms under-
pinning the process of endothelial-
to-mesenchymal transition (EndMT)
are mostly unknown. Recently
Xiong and colleagues explored for
the first time the metabolic changes
associated with the activation of the
mesenchymal program in endothe-
lial cells, and found that reprogram-
ming of fatty acid oxidation pivotally
regulates EndMT.
EndMT is the cellular transdifferentiation
program by which endothelial cells
acquire mesenchymal features, including
loss of cell–cell junctions and the acquisi-
tion of a fibroblast-like morphology and
gene expression profile. Originally
described as being physiologically impor-
tant for the formation of the heart valves
[1], EndMT was subsequently discovered
to be important in the pathological setting
of cardiac fibrosis [2], and eventually as a
key driver of many different pathologies
[3–5]. Features of EndMT have been
mainly inferred by analogy from the pro-
cess of epithelial-to-mesenchymal transi-
tion (EMT), and very limited knowledge is
available about the molecular mecha-
nisms uniquely defining EndMT [6].
A recent publication by the group of Toren
Finkel has now identified metabolic alter-
ations that accompany the activation of
the EndMT program [7]. Metabolic
profiling of human pulmonary microvascu-
lar endothelial cells (HPMVECs) stimulated
to undergo EndMT by combined treat-
ment with TGF-b1 and IL-1b revealed a
marked reduction of endothelial fatty acid
oxidation (FAO) following cytokine stimu-
lation. This metabolic change was charac-
terized by an early rapid decline in the level
of carnitine O-palmitoyltransferase 1
(CPT1A), a rate-limiting enzyme located
in the outer mitochondrial membrane
whose function is indispensable for mito-
chondria-dependent b-oxidation of long-
chain fatty acids. Exogenous
overexpression of CPT1A was able to
block the induction of EndMT following
TGF-b1 plus IL-1b treatment, whereas
inhibition of FAO by shRNA-mediated
CPT1A silencing was sufficient to activate
the EndMT program by potentiating
endogenous TGF-b signaling. In search
for potential molecular mechanisms
explaining the observed FAO-dependent
modulation of EndMT, the authors found
that cytokine induction of EndMT resulted
in low levels of acetyl-CoA. Modulating the
levels of acetyl-CoA by either acetate sup-
plementation or pharmacological inhibition
resulted, respectively, in the suppression
or activation of TGF-b-induced EndMT.
The study also showed that the capacity
of acetyl-CoA to function as a sensor for
EndMT susceptibility is exerted by post-
translationally controlling SMAD7, a
potent inhibitor of TGF-b signaling. In fact,
the authors demonstrated that acetyl-
CoA, and hence FAO, are required to
induce SMAD7 acetylation and conse-
quently to maintain its stability, therefore
promoting the suppression of TGF-b sig-
naling. To validate the physiological rele-
vance of these in vitro findings, Xiong and
coworkers generated a mouse model to
genetically target FAO specifically in endo-
thelial cells by crossing mice carrying the
Cpt2 conditional knockout allele with VE-
cadherin Cre+ mice. Consistent with the
data collected from the human
endothelial cell lines, primary lung endo-
thelial cells isolated from Cpt2E-KO mice
displayed reduced acetyl-CoA levels and
constitutive activation of the TGF-b-asso-
ciated SMAD signaling, which could be
reverted by acetate supplementation. In
vivo endothelial inhibition of FAO caused
a marked thickening of the heart mitral
valve and, consistent with the known role
of EndMT during heart development, line-
age-tracing analysis confirmed that this
phenotype was a consequence of
increased EndMT in Cpt2E-KO embryos.
In adult mice, increased incidence of
endothelial cells undergoing mesenchy-
mal transition was detected in organs
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